Skip to content
OpenCapital
Get started

Entrada Therapeutics TRDA Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

Revenue$37.4MBeat by $24.3M
EPS$0.03Beat by $0.69
Revenue estimate$13.1M
EPS estimate-$0.66

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$2.2M
EPS estimate-$1.05

Versus estimates

Revenue

Q1 2026$875.0KMiss by $2.0MQ4 2025$1.3MMiss by $6.1MQ3 2025$1.6MMiss by $6.9MQ2 2025$2.0MMiss by $5.9MQ1 2025$20.6MBeat by $10.8M
Q4 2024$37.4MBeat by $24.3M

Diluted EPS

Q1 2026-$0.95Beat by $0.11Q4 2025-$0.94Beat by $0.38Q3 2025-$1.06Miss by $0.02Q2 2025-$1.04Miss by $0.18Q1 2025-$0.42Beat by $0.36
Q4 2024$0.03Beat by $0.69

Ask the moment Entrada Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Entrada Therapeutics report Q4 2024 earnings?
Entrada Therapeutics (TRDA) reported Q4 2024 earnings on February 27, 2025 before market open.
What were Entrada Therapeutics's Q4 2024 revenue and EPS?
Entrada Therapeutics reported revenue of $37.4M and eps of $0.03 for Q4 2024.
Did Entrada Therapeutics beat estimates in Q4 2024?
Revenue beat the consensus estimate of $13.1M by $24.3M. EPS beat the consensus estimate of $-0.66 by $0.69.
Where can I find Entrada Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001689375-25-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.